Ghent University Academic Bibliography

Show Sort by

Your filters: cql: author="Ghia, P" or (type exact bookEditor and editor="Ghia, P")

Add to list
- Conference Paper
- C3
Phase 3 study of ibrutinib as first-line treatment in older patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) : a 4-year follow-up from the RESONATE-2 study

JA Burger, PM Barr, T Robak, C Owen, P Ghia, A Tedeschi, O Bairey, P Hillmen, SE Coutre, S Devereux, et al.

(2018) ONCOLOGY RESEARCH AND TREATMENT. 41(suppl. 4). p.29-29
Add to list
- Conference Paper
- C3
Improvement in hematologic function, disease burden/symptoms with ibrutinib in older treatment-naive (TN) patients with chronic lymphocytic leukemia (CLL) in phase 3 RESONATE-2 (TM)

P Barr, T Kipps, T Robak, A Tedeschi, C Owen, P Ghia, P Hillmen, Fritz Offner (UGent) , C Moreno, C Zhou, et al.

(2016) JOURNAL OF THE AMERICAN GERIATRICS SOCIETY. 64(suppl. 1). p.S79-S79
Add to list
- Conference Paper
- C3
Improvement in quality of life and well-being in older patients with treatment-naive (TN) CLL : results from the randomized phase 3 study of ibrutinib (IBR) versus chlorambucil (CLB) (resonate-2™)

P Ghia, A Tedeschi, PM Barr, T Robak, C Owen, O Bairey, P Hillmen, NL Bartlett, J Li, D Simpson, et al.

(2016) HAEMATOLOGICA. 101(suppl. 1). p.55-56
Add to list
- Conference Paper
- C3
International, randomized phase 3 study results : Ibrutinib versus Chlorambucil in patients 65 years and older with treatment-naive CLL (RESONATE-2 (TM))

J Burger, A Tedeschi, PM Barr, T Robak, C Owen, P Ghia, O Bairey, P Hillmen, NL Bartlett, J Li, et al.

(2016) ONCOLOGY RESEARCH AND TREATMENT. 39(suppl. 3). p.6-6
Add to list
- Conference Paper
- C3
Results from the international, randomized phase 3 study of ibrutinib versus chlorambucil in patients 65 years and older with treatment-naive (TN) CLL/SLL (RESONATE-2 (TM))

P Hillmen, A Tedeschi, PM Barr, T Robak, C Owen, P Ghia, O Bairey, NL Bartlett, J Li, D Simpson, et al.

(2016) BRITISH JOURNAL OF HAEMATOLOGY. 173(suppl. 1). p.7-7
Add to list
Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia

JA Burger, A Tedeschi, PM Barr, T Robak, C Owen, P Ghia, O Bairey, P Hillmen, NL Bartlett, J Li, et al.

(2015) NEW ENGLAND JOURNAL OF MEDICINE. 373(25). p.2425-2437

Academic Bibliography

Phase 3 study of ibrutinib as first-line treatment in older patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) : a 4-year follow-up from the RESONATE-2 study

Improvement in hematologic function, disease burden/symptoms with ibrutinib in older treatment-naive (TN) patients with chronic lymphocytic leukemia (CLL) in phase 3 RESONATE-2 (TM)

Improvement in quality of life and well-being in older patients with treatment-naive (TN) CLL : results from the randomized phase 3 study of ibrutinib (IBR) versus chlorambucil (CLB) (resonate-2™)

International, randomized phase 3 study results : Ibrutinib versus Chlorambucil in patients 65 years and older with treatment-naive CLL (RESONATE-2 (TM))

Results from the international, randomized phase 3 study of ibrutinib versus chlorambucil in patients 65 years and older with treatment-naive (TN) CLL/SLL (RESONATE-2 (TM))

Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia

Contents

Support

Contact